Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
BCMA Double Nickase Plasmid (h): sc-403058-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- BCMA Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- BCMA Double Nickase Plasmid (h) and BCMA Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting TNFRSF17. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: BCMA Antibody (D-6): sc-390147
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BCMA Double Nickase Plasmid (h) | sc-403058-NIC | 20 µg | $410.00 | |||
BCMA Double Nickase Plasmid (h2) | sc-403058-NIC-2 | 20 µg | $410.00 |
TNFRSF17 encodes B-cell maturation antigen (BCMA), a TNF receptor superfamily member predominantly expressed on late-stage B cells and plasma cells. BCMA binds APRIL and BAFF to activate NF-κB and related survival programs that support antibody-secreting cell maintenance, immunoglobulin production, and plasma cell longevity within the bone marrow niche. Dysregulated BCMA signaling and expression are closely linked to aberrant plasma cell expansion and B-cell lineage pathology, making it a key node for studying humoral immunity, B-cell differentiation, and microenvironment-dependent survival pathways. As a surface receptor with well-defined ligands and downstream effectors, BCMA provides a tractable target for interrogating receptor-mediated signaling and transcriptional responses in human immune cells.
BCMA Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the TNFRSF17 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within TNFRSF17. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt TNFRSF17 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of TNFRSF17-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.